AFT sees 24% hike in sales  

Flagship Maxigesic products and Australian OTC business contribute the most to latest half yearly results Maxigesic manufacturer AFT Pharmaceuticals has reported higher bottom-line profit and revenue after continued robust demand for its combo painkiller both in Australasia and internationally. In its latest half-yearly results, it reported a 24% increase in sales from existing drugs, new